Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06524739 · ClinicalTrials.gov registry record · Phase 3
Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
A Phase 3 study, sponsored by CSL Behring.
- Terminated
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
NCT06524739 is a Phase 3 study that was terminated before completion, run by CSL Behring. The registered enrollment target is 16 participants.
The verdict
NCT06524739, a Phase 3 study, was terminated before completion, sponsored by CSL Behring.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a prospective, phase 3, multicenter, double-blind, randomized placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics (PK) of repeat doses of IgPro20 in participants with post SARS-CoV-2 infection 2019 postural orthostatic tachycardia syndrome (post-Coronavirus Disease 2019 \[COVID-19\] POTS \[post-COVID-POTS\]).
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL IgPro20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2024-08-28 |
| Est. Completion | 2025-07-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06524739
The ClinicalTrials.gov registry entry for NCT06524739 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06524739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06524739 about?
NCT06524739 is a clinical study titled "Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS". This is a prospective, phase 3, multicenter, double-blind, randomized placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics (PK) of repeat doses of IgPro20 in participants with post SARS-CoV-2 infection 2019 postural orthostatic tachycardia syndrome (post-Coronavirus Dis...
What is the current status of trial NCT06524739?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2024-08-28. Estimated completion is 2025-07-11.
What interventions are being tested in trial NCT06524739?
The interventions under investigation include: Placebo (BIOLOGICAL), IgPro20 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06524739?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.